SITC Meeting | Conference

Dr. Luke on Combining an IDO Inhibitor With Nivolumab in Advanced Cancers

November 12th 2017

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses a study evaluating the IDO1 inhibitor BMS-986205 as a monotherapy and in combination with nivolumab in patients with advanced cancers.

Nivolumab Spurs Responses in non-CRC Patients With dMMR

November 11th 2017

Nivolumab demonstrated a 24% overall response rate among patients with a range of non-colorectal cancers with mismatch repair deficiency who were identified through the NCI-MATCH trial.

JCAR015 Experience Informs Future CAR-T Studies

November 11th 2017

The high rates of cerebral edema seen with JCAR015 in the phase II ROCKET trial were attributed to early and rapid chimeric antigen receptor (CAR)-modified T-cell expansion and a rise in interleukin-15 levels, a finding that could help inform future CAR T-cell usage.

Combinations Required to Further Advance Adoptive T-Cell Therapy

November 10th 2017

A variety of adoptive T-cell therapy strategies have shown promise in clinical studies with recent FDA approvals granted to CAR-modified T-cell therapies, representing the potential for future combination strategies.

Emerging Immune Checkpoint Holds Promise for Blockade Strategies

November 30th 2016

A novel immune checkpoint called PVRIG is currently in development.

Sonja Althammer on Role of CD8 and PD-L1 Biomarkers for Immunotherapy in NSCLC

November 17th 2016

Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, Munich, Bavaria, Germany, discusses a study looking to define a subgroup of patients with non–small cell lung cancer (NSCLC) who respond well to treatment with the PD-L1 inhibitor durvalumab.

Susan Lutgendorf on Impact of Minimal Support on Patients With Ovarian Cancer

November 16th 2016

Susan Lutgendorf, PhD, professor and Starch Faculty Fellow, Psychological and Brain Sciences, College of Liberal Arts and Sciences, University of Iowa, discusses the impact of lack of support on patients with ovarian cancer. Lutgendorf spoke on this during an interview at the SITC 31st Annual Meeting and Associated Programs.

Lisa Butterfield on SITC Immune Biomarkers Task Force

November 16th 2016

Lisa Butterfield, PhD, professor of Medicine, Surgery and Immunology, director, University of Pittsburgh Cancer Institute Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, discusses the goals of the Society for Immunotherapy of Cancer (SITC) Immune Biomarkers Task Force during an interview at the SITC 31st Annual Meeting and Associated Programs.

Dual Biomarker Signature Holds Predictive Promise for Response to Anti-PD-L1 Therapy in NSCLC

November 16th 2016

Recent research suggests that the presence of PD-L1–positive and CD8+ cells may be useful for predicting responses in patients with non-small cell lung cancer who have been treated with durvalumab.

Nivolumab/Ipilimumab Combo Highly Effective for Pretreated Metastatic Urothelial Carcinoma

November 14th 2016

The combination of nivolumab and ipilimumab led to a high response rate and improved overall survival versus historical controls for patients with pretreated metastatic urothelial carcinoma.

Pembrolizumab OS Benefit Sets New Benchmark in Second-Line Bladder Cancer

November 13th 2016

Pembrolizumab monotherapy reduced the risk of death by 27% compared with chemotherapy for patients with advanced urothelial carcinoma whose disease progressed after prior treatment.

Lirilumab/Nivolumab Combo Highly Effective in Head and Neck Cancer

November 13th 2016

The combination of lirilumab and nivolumab resulted in an objective response rate of 24.1% in patients with squamous cell carcinoma of the head and neck.

Dr. Bellmunt Shares KEYNOTE-045 Data for Pembrolizumab Versus Chemotherapy in Bladder Cancer

November 13th 2016

Joaquim Bellmunt, MD, PhD, attending physician of Solid Tumor Oncology at Dana-Farber Cancer Institute, discusses findings from the phase III KEYNOTE-045 study, which compared second- or third-line pembrolizumab with investigator-choice chemotherapy as a treatment for patients with metastatic or locally advanced, unresectable urothelial carcinoma.